Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Jun 25, 2023 10:39pm
294 Views
Post# 35513970

RE:RE:90 days

RE:RE:90 daysScooter on ST did a pretty deep dive into colorectal cancer and came up with some pretty interesting stuff. 
 
Matt said in one of his recent interviews that " It probably works in colorectal."   

They put pancreatic cancer, colorectal and anal together as  a group hoping to get something positive out of it.

The Pancreatic results were a surprise. Dr Vile said in the breast cancer KOL that the order in which therapies are given are important.

I think Roche has stumbled onto something quite interesting in Pancreatic cancer. If they knew they were onto something beforehand they would have had Pancreatic on its own as a separate entity in my opinion. 

Colorectal is the second biggest cancer market right now.
A hit there as well would be a home run hit out of the park in my opinion.

Takeda is probably getting a new FDA approval in November for  drug for colorectal it looks like. So other companies will want to compete there most likely. There's been no new real treatments for metastatic colorectal in the past ten years according to the Takeda news release. 

Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!





.
<< Previous
Bullboard Posts
Next >>